Reagan-Udall pushback
This article was originally published in The Gray Sheet
Executive Summary
Rep. Rosa DeLauro, D-Conn., wants FDA to halt efforts to establish the Reagan-Udall Foundation, a non-profit created by the recently enacted FDA Amendments Act. "The potential for pressure on FDA staff from Reagan-Udall Foundation-endorsed research is enormous," the chair of the House subcommittee overseeing FDA's budget writes in a Nov. 1 letter to Commissioner Andrew von Eschenbach. The foundation, to be funded from donations, patent revenue and FDA's budget, is tasked to work with FDA on its Critical Path initiative and other efforts to speed product development (1"The Gray Sheet" Oct. 8, 2007, p. 9). By law, four members of the yet-unnamed 14-person foundation board have to be from the device, drug, biotech, cosmetic and food industries
You may also be interested in...
Regulatory News In Brief
DeLauro targets ortho ads: Rep. Rosa DeLauro, D-Conn., says she may introduce a bill banning direct-to-consumer advertising for hip and knee implants for three years post-FDA approval. She has previously sponsored similar, unsuccessful legislation on drugs alone, but at an Oct. 3 speech at George Washington University, she cited a "new concern" with hip and knee ads "giving no indication of the potential complications and side effects from the major surgery they require." DeLauro, chair of the House appropriations panel that oversees FDA's budget, has noted that her own upcoming hip replacement surgery drew her to the issue. Her speech was mainly about a proposal to create a distinct Food Safety Administration and rename the rest of FDA the Federal Drug and Device Administration
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs
There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under- and uninsured patients once the US switches to a commercial market for COVID vaccines – a sign of broader frustration with industry copay support initiatives.